Literature DB >> 21287545

PI3Kγ deficiency delays the onset of experimental autoimmune encephalomyelitis and ameliorates its clinical outcome.

Luciana Berod1, Christina Heinemann, Sylvia Heink, Angelika Escher, Christine Stadelmann, Sebastian Drube, Reinhard Wetzker, Johannes Norgauer, Thomas Kamradt.   

Abstract

PI3Ks control signal transduction triggered by growth factors and G-protein-coupled receptors and regulate an array of biological processes, including cellular proliferation, differentiation, survival and migration. Herein, we investigated the role of PI3Kγ in the pathogenesis of EAE. We show that, in the absence of PI3Kγ expression, clinical signs of EAE were delayed and mitigated. PI3Kγ-deficient myelin oligodendrocyte glycoprotein (MOG)(35-55) -specific CD4(+) T cells appeared later in the secondary lymphoid organs and in the CNS than their WT counterparts. Transfer of WT CD4(+) cells into PI3Kγ(-/-) mice prior to MOG(35-55) immunisation restored EAE severity to WT levels, supporting the relevance of PI3Kγ expression in Th cells for the pathogenesis of EAE; however, PI3Kγ was dispensable for Th1 and Th17 differentiation, thus excluding an altered expression of these pathogenetically relevant cytokines as the cause for ameliorated EAE in PI3Kγ(-/-) mice. These findings demonstrate that PI3Kγ contributes to the development of autoimmune CNS inflammation.
Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21287545     DOI: 10.1002/eji.201040504

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  18 in total

Review 1.  Metabolic control of the Treg/Th17 axis.

Authors:  Joseph Barbi; Drew Pardoll; Fan Pan
Journal:  Immunol Rev       Date:  2013-03       Impact factor: 12.988

2.  ZSTK474, a novel PI3K inhibitor, modulates human CD14+ monocyte-derived dendritic cell functions and suppresses experimental autoimmune encephalomyelitis.

Authors:  Zhenyi Xue; Wen Li; Huafeng Wang; Biao Huang; Zhenzhen Ge; Chao Gu; Ying Liu; Kai Zhang; Juhong Yang; Rong Han; Meiyu Peng; Yan Li; Da Zhang; Yurong Da; Zhi Yao; Rongxin Zhang
Journal:  J Mol Med (Berl)       Date:  2014-05-22       Impact factor: 4.599

3.  Duvelisib, an oral dual PI3K-δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study.

Authors:  Susan O'Brien; Manish Patel; Brad S Kahl; Steven M Horwitz; Francine M Foss; Pierluigi Porcu; Jeffrey Jones; Jan Burger; Nitin Jain; Kerstin Allen; Kerrie Faia; Mark Douglas; Howard M Stern; Jennifer Sweeney; Patrick Kelly; Virginia Kelly; Ian Flinn
Journal:  Am J Hematol       Date:  2018-10-20       Impact factor: 10.047

4.  Control of CD4+ T Cell Differentiation and Function by PI3K Isoforms.

Authors:  Benjamin Cameron; Syed Aymaan Zaheer; Margarita Dominguez-Villar
Journal:  Curr Top Microbiol Immunol       Date:  2022       Impact factor: 4.737

5.  De novo fatty acid synthesis controls the fate between regulatory T and T helper 17 cells.

Authors:  Luciana Berod; Christin Friedrich; Amrita Nandan; Jenny Freitag; Stefanie Hagemann; Kirsten Harmrolfs; Aline Sandouk; Christina Hesse; Carla N Castro; Heike Bähre; Sarah K Tschirner; Nataliya Gorinski; Melanie Gohmert; Christian T Mayer; Jochen Huehn; Evgeni Ponimaskin; Wolf-Rainer Abraham; Rolf Müller; Matthias Lochner; Tim Sparwasser
Journal:  Nat Med       Date:  2014-10-05       Impact factor: 53.440

6.  Pten loss in CD4 T cells enhances their helper function but does not lead to autoimmunity or lymphoma.

Authors:  Dalya R Soond; Fabien Garçon; Daniel T Patton; Julia Rolf; Martin Turner; Cheryl Scudamore; Oliver A Garden; Klaus Okkenhaug
Journal:  J Immunol       Date:  2012-05-18       Impact factor: 5.422

7.  The Therapeutic Potential for PI3K Inhibitors in Autoimmune Rheumatic Diseases.

Authors:  Edward Banham-Hall; Menna R Clatworthy; Klaus Okkenhaug
Journal:  Open Rheumatol J       Date:  2012-09-07

8.  PI3Kγ drives priming and survival of autoreactive CD4(+) T cells during experimental autoimmune encephalomyelitis.

Authors:  Iain Comerford; Wendel Litchfield; Ervin Kara; Shaun R McColl
Journal:  PLoS One       Date:  2012-09-13       Impact factor: 3.240

9.  PI3Kγ inhibition alleviates symptoms and increases axon number in experimental autoimmune encephalomyelitis mice.

Authors:  H Li; D Park; P M Abdul-Muneer; B Xu; H Wang; B Xing; D Wu; S Li
Journal:  Neuroscience       Date:  2013-09-03       Impact factor: 3.708

10.  The Role of the PI3K Signaling Pathway in CD4(+) T Cell Differentiation and Function.

Authors:  Jonathan M Han; Scott J Patterson; Megan K Levings
Journal:  Front Immunol       Date:  2012-08-13       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.